Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Price Down 6% – Here’s Why

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) fell 6% during mid-day trading on Tuesday . The stock traded as low as $43.11 and last traded at $43.22. 1,415,651 shares changed hands during mid-day trading, an increase of 89% from the average session volume of 749,782 shares. The stock had previously closed at $46.00.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on SUPN shares. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Cantor Fitzgerald boosted their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $62.83.

Supernus Pharmaceuticals Price Performance

The stock has a market cap of $2.72 billion, a price-to-earnings ratio of -24.35, a price-to-earnings-growth ratio of 0.85 and a beta of 0.56. The firm’s 50-day moving average is $46.14 and its 200 day moving average is $48.96.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL purchased a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at $1,434,000. Phocas Financial Corp. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth about $4,042,000. Westover Capital Advisors LLC purchased a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $1,587,000. Elmind Capital LP purchased a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $994,000. Finally, Aberdeen Group plc acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth $13,497,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.